Strategic Acquisition Drugscan was acquired by ACM Global Laboratories in late 2017, highlighting potential integration opportunities with larger lab networks and cross-sell of toxicology, infectious disease testing, and addiction monitoring services to a broader enterprise client base.

Expansion Readiness Operating in 48 states with CAP and SAMSHA-certified labs suggests capacity for scaled testing programs, making Drugscan a fit for nationwide employers and multi-site organizations seeking standardized workplace drug testing and infectious disease screening.

Workplace Testing Focus Strong emphasis on prescription monitoring, addiction testing, and workplace drug testing programs positions sales conversations around compliance, program management, and remote monitoring capabilities for HR and safety leads.

Infectious Disease Capabilities ViraScan real-time PCR infectious disease testing capability, including COVID-19, offers cross-sell opportunities into clients requiring ongoing infectious disease surveillance, employee screening, and public health partnerships.

Market Positioning Mid-market laboratory with revenue indicator in the tens of millions, suggesting a competitive target for mid-size employers and healthcare providers looking for cost-effective, scalable testing solutions aligned with larger lab networks.